The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (M pro ) exemplifies this accelerated approach and reminds us of the needs and opportunities for addressing this pandemic. ABSTRACT The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (M pro ) exemplifies this accelerated approach and reminds us of the needs and opportunities for addressing this pandemic.
【저자키워드】 COVID-19, SARS-CoV-2, coronavirus, protease inhibitors, Antiviral agents, hepatitis C virus, drug resistance, Human immunodeficiency virus, 【초록키워드】 HIV, pandemic, protease, antiviral drug, morbidity and mortality, inhibitor, M pro, approach, effective, less, magnitude, accelerate, accelerated, 【제목키워드】 drug, address,